Simpa S Salami, MD, MPH
Manage Your Profile
About
Simpa S. Salami, M.D., M.P.H. is a fellowship-trained, board-certified Urologic Oncologist and Associate Professor of Urology at the University of Michigan. He obtained his medical degree from the College of Medicine, University of Ibadan, Nigeria. Thereafter, he completed a Master of Public Health program at Harvard University, General Surgery Internship at the Brigham and Women’s Hospital in Boston, Urology Residency at Hofstra Northwell Health School of Medicine in New York, and Urologic Oncology Fellowship at the University of Michigan in Ann Arbor, Michigan. Dr. Salami’s clinical expertise is in the minimally invasive surgical treatment of prostate and kidney cancer. As a translational surgeon-scientist, his laboratory focuses on developing novel cancer biomarkers to overcome tumor heterogeneity and multifocality as well as elucidate optimal paradigms for early detection of urologic cancers, risk stratification, prognostication, and prediction of treatment response. Dr. Salami’s lab collaborates with investigators all over the world to understand the molecular underpinnings of urologic cancer and associated disparities. Dr. Salami is a recipient of several awards including the: Harvard University Presidential Scholar, Prostate Cancer Foundation Young Investigator, American Urological Association (AUA) Urology Care Foundation (UCF) Research Scholar, AUA UCF Rising Stars in Urologic Research, Harold Amos Medical Faculty Development Fellowship, Rogel Cancer Center Scholar, Society of Urologic Oncology Young Investigator, NCI R37 MERIT and 2024 AUA Gold Cystoscope Awards. Most recently, he was named an inaugural Biden White House Cancer Moonshot Scholar. He has served on several National guideline committees, such as the AUA Prostate Cancer Early Detection Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, and the Society of Nuclear Medicine and Imaging PSMA PET Appropriate Use Criteria Working Group. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and the Prostate Cancer Foundation.
Links
Urology Department Profile twitter linkedin
Qualifications
-
Innovation Nexus BootcampAmerican Urological Association, Linthicum, Maryland, United States
2023 - 2023
-
MPHHarvard University School of Public Health, 677 Huntington Ave, Boston, Massachusetts, 02215, United States
2008 - 2009
-
MDUniversity of Ibadan, College of Medicine, Ibadan, Oyo State, Nigeria, Nigeria
2000 - 2006
Center Memberships
-
Center MemberTaubman Institute
-
Center MemberAI and Digital Health Innovation
-
Center MemberRogel Cancer Center
-
Center MemberCenter for Global Health Equity
-
Center MemberGlobal REACH
Research Overview
My research focuses on improving the early detection and treatment of prostate and kidney cancers through the discovery of novel actionable biomarkers. By integrating sophisticated molecular profiling and computational approaches, my lab aims to refine risk stratification, predict treatment response, and develop personalized medicine strategies to improve urologic cancer outcomes.
Recent Publications
-
Tosoian JJ, Penson DF, Ross AE, Salami SS, Meyers JI, Chinnaiyan AM. J Urol, 2026 Oct 15; 101097JU0000000000005332Journal ArticleReply: Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison With MRI.
DOI:10.1097/JU.0000000000005332 PMID: 42879247 -
Rozet F, Mckay RR, Ross AE, Preston MA, Gregg JR, Salami SS, Saad F, Pieczonka CM, Tutrone RF, Hamilton J, Morris DS, Belkoff LH, Lance RS, Littleton N, Constantinovici N, Srinivasan S, Verholen F, Shore ND. Progrès en Urologie - FMC, 2026 Oct 31; 36 (7): s24 - s25.Journal ArticleDarolutamide associé à une suppression androgénique (ADT) dans le cancer de la prostate métastatique hormono-sensible (CPHSm) : ARASEC – Étude prospective de phase II en ouvert avec un bras contrôle externe
DOI:10.1016/j.fpurol.2026.07.038 -
Wang B, Mukherjee S, Baj A, Trostel SY, Lis RT, Whitlock NC, Ku AT, Heyward KE, Kartal S, Wang K, Voznesensky OS, Calagua C, Siddiqui J, Martin RS, Kollath LA, Custer J, Michael PD, Kunju LP, Lake R, Harris CC, Aldape KD, True LD, Tatsuoka C, Fertig EJ, Chinnaiyan A, Gurram S, Pinto PA, Weiner AB, Morrissey C, Salami SS, Einstein DJ, Balk SP, Sowalsky AG, Ruppin E. 2026 Aug 31;PreprintTumor-adjacent B cell infiltration stratifies recurrence risk in localized prostate cancer.
DOI:10.64898/2026.08.29.26361718 PMID: 42922617 -
Leni R, Eggener SE, Cooperberg MR, Salami SS, Weiner AB, Zhou M, Al-Sattar H, Lamb AD, Vickers AJ. BJU International, 2026 Jan 1;Journal ArticleIs Gleason pattern 3 cancer? Molecular features do not distinguish pattern 3 from benign tissue
DOI:10.1111/bju.70433 PMID: 42750341 -
Stangl-Kremser J, Salami SS. European Urology Focus, 2026 Jan 1;Journal ArticleRisk-stratified Prostate Cancer Screening in 2026: Blood- and Urine-based Biomarkers
DOI:10.1016/j.euf.2026.10.007
Featured News & Stories
Endowed Professorship Ceremony
Medical School Honors Three Faculty Members with Endowed Professorships
Michigan Urology Global Health Update